These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 39372412)

  • 1. Generating advanced CAR-based therapy for hematological malignancies in clinical practice: targets to cell sources to combinational strategies.
    Zhou S; Yang Y; Jing Y; Zhu X
    Front Immunol; 2024; 15():1435635. PubMed ID: 39372412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR T Cell Therapy for Hematological Malignancies.
    Yang X; Wang GX; Zhou JF
    Curr Med Sci; 2019 Dec; 39(6):874-882. PubMed ID: 31845217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAR-T cells: the Chinese experience.
    Wang L; Tan Su Yin E; Zhao H; Ni F; Hu Y; Huang H
    Expert Opin Biol Ther; 2020 Nov; 20(11):1293-1308. PubMed ID: 32605454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
    Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
    Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in CAR-NK cell therapy for hematological malignancies.
    Yang R; Yang Y; Liu R; Wang Y; Yang R; He A
    Front Immunol; 2024; 15():1414264. PubMed ID: 39007146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies.
    Liu Y; Peng C; Ahad F; Ali Zaidi SA; Muluh TA; Fu Q
    Recent Pat Anticancer Drug Discov; 2024; 19(5):557-572. PubMed ID: 38213150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Advances in CAR-T Therapy.
    Ali MB
    Cancer Control; 2024; 31():10732748241263713. PubMed ID: 38910268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis.
    Luo W; Li C; Zhang Y; Du M; Kou H; Lu C; Mei H; Hu Y
    BMC Cancer; 2022 Jan; 22(1):98. PubMed ID: 35073859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges.
    Zhang X; Zhu L; Zhang H; Chen S; Xiao Y
    Front Immunol; 2022; 13():927153. PubMed ID: 35757715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How can we improve the successful identification of patients suitable for CAR-T cell therapy?
    Feng Y; Wu L; Gu T; Hu Y; Huang H
    Expert Rev Mol Diagn; 2024 Sep; 24(9):777-792. PubMed ID: 39258858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Charting new paradigms for CAR-T cell therapy beyond current Achilles heels.
    Li Y; Hu Z; Li Y; Wu X
    Front Immunol; 2024; 15():1409021. PubMed ID: 38751430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
    Nguyen S; Lacan C; Roos-Weil D
    Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in CAR-T-cell therapy in T-cell malignancies.
    Zheng R; Zhu X; Xiao Y
    J Hematol Oncol; 2024 Jun; 17(1):49. PubMed ID: 38915099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The journey of CAR-T therapy in hematological malignancies.
    Lu J; Jiang G
    Mol Cancer; 2022 Oct; 21(1):194. PubMed ID: 36209106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress.
    Holstein SA; Lunning MA
    Clin Pharmacol Ther; 2020 Jan; 107(1):112-122. PubMed ID: 31622496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies.
    Shen C; Zhang Z; Zhang Y
    Biomed Res Int; 2020; 2020():8765028. PubMed ID: 33150182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanding the role of CAR T-cell therapy: From B-cell hematological malignancies to autoimmune rheumatic diseases.
    Shumnalieva R; Velikova T; Monov S
    Int J Rheum Dis; 2024 May; 27(5):e15182. PubMed ID: 38742463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies.
    Al Hadidi S; Heslop HE; Brenner MK; Suzuki M
    Mol Ther; 2024 Aug; 32(8):2444-2460. PubMed ID: 38822527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive therapy with CAR redirected T cells for hematological malignancies.
    Li S; Yang Z; Shen J; Shan J; Qian C
    Sci China Life Sci; 2016 Apr; 59(4):370-8. PubMed ID: 27009302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.